Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of pl...
Leadership
Martin Babler Ph.D.
President, CEO & Chairman
David M. Goldstein Ph.D.
Chief Scientific Officer
Jorn Drappa M.D., Ph.D.
Chief Medical Officer & Head of Research and Development
John R. Schroer C.F.A.
Chief Financial Officer
Sanam Pangali J.D.
Chief Legal Officer & Corporate Secretary
Roy C. Hardiman J.D.
Chief Business & Strategy Officer
Claire Langrish Ph.D.
Senior VP & Head of Immunology and Translational Science
